Walleye Capital
PACB icon

Walleye Capital’s Pacific Biosciences PACB Stock Holding History

Walleye Capital’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$37.4K – 4813
2025
Q4 		$37.4K Buy
+20,000
New +$38.4K ﹤0.01% 4146
2025
Q1 		– Sell
-4,000
Closed -$7.32K – 4896
2024
Q4 		$7.32K Hold
4,000
– – ﹤0.01% 4604
2024
Q3 		$6.8K Sell
4,000
-212,300
-98% -$349K ﹤0.01% 4965
2024
Q2 		$296K Sell
216,300
-42,000
-16% -$84.8K ﹤0.01% 3987
2024
Q1 		$969K Buy
258,300
+226,200
+705% +$1.32M ﹤0.01% 2620
2023
Q4 		$315K Sell
32,100
-3,900
-11% -$31.9K ﹤0.01% 3338
2023
Q3 		$301K Sell
36,000
-20,600
-36% -$235K ﹤0.01% 3237
2023
Q2 		$753K Buy
56,600
+34,800
+160% +$423K ﹤0.01% 2091
2023
Q1 		$252K Buy
+21,800
New +$217K ﹤0.01% 2268

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Walleye Capital's PACB Position: Q1 2025 in Review

Walleye Capital sold out of Pacific Biosciences (PACB) in Q1 2025, closing a stake of 1,943,046 shares — an estimated $3.56M sold.

Walleye Capital first reported a position in PACB in Q2 2020 and held it in 10 quarters. The position peaked at $3.56M in Q4 2024. 225 funds tracked by Wall St. Rank hold PACB as of Q1 2025.

  • Walleye Capital reported no remaining Pacific Biosciences position as of Q1 2025 after selling out during the quarter.
  • Walleye Capital sold 1,943,046 Pacific Biosciences shares in Q1 2025, an estimated $3.56M.
  • Walleye Capital first reported a position in Pacific Biosciences in Q2 2020 and held it in 10 quarters.
  • Walleye Capital's Pacific Biosciences position peaked at $3.56M in Q4 2024.
  • 225 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.